



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

January 21, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Certificate pursuant to Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.

With reference to the subject captioned above, please find enclosed herewith the Reconciliation of Share Capital Audit Report pursuant to Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.

Kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

To,

The Board of Directors,

SUPRIYA LIFESCIENCE LIMITED.

207/208, Udyog Bhavan,

Sonawala Road, Goregaon (E),

Mumbai - 400 063.

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

| | |
|---|--|
| 1. For Quarter Ended | 31st December, 2025 |
| 2. ISIN | INE07RO01027 |
| 3. Face Value | Rs.2/- |
| 4. Name of the Company | SUPRIYA LIFESCIENCE LIMITED |
| 5. Registered Office Address | 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400 063, Maharashtra. |
| 6. Correspondence Address | 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400 063, Maharashtra. |
| 7. Telephone & Fax Nos. | Telephone- 022-4033 2727 |
| 8. Email address | cs@supriyalifescience.com |
| 9. Names of the Stock Exchanges where the company's securities are listed: | Bombay Stock Exchange Limited ("BSE") and National Stock Exchange of India Limited ("NSE") |

| 10. Issued Capital | Number of Shares | % of Total Issued Capital |
|---------------------------|------------------|---------------------------|
| | 8,04,82,800 | 100% |

| | |
|--|-------------|
| 11. Listed Capital (Exchange-wise) (as per company records) | 8,04,82,800 |
|--|-------------|

| | | |
|--|-------------|--------|
| 12. Held in dematerialised form in CDSL | 6,49,41,278 | 80.69% |
|--|-------------|--------|

| | | |
|--|-------------|--------|
| 13. Held in dematerialised form in NSDL | 1,55,41,522 | 19.31% |
|--|-------------|--------|

| | | |
|---------------------|---|-------|
| 14. Physical | 0 | 0.00% |
|---------------------|---|-------|

| | | |
|---|-------------|------|
| 15. Total No. of shares (12+13+14) | 8,04,82,800 | 100% |
|---|-------------|------|

| | |
|---|------|
| 16. Reasons for difference if any, between (10&11), (10&15), (11&15) | N.A. |
|---|------|

17. **Certifying the details of changes in share capital during the quarter under consideration as per Table below:**

| Particulars* | No. of shares | Applied / Not Applied for listing | Listed on Stock Exchanges (Specify Names) | Whether intimate d to CDSL | Whether intimate d to NSDL | In-prin. appr. pending for SE (Specify Names) |
|----------------|---------------|-----------------------------------|---|----------------------------|----------------------------|---|
| Not Applicable | | | | | | |

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction Forfeiture, any other (to specify).

18. **Register of Members is updated (Yes / No)** Yes
If not, updated upto which date

19. **Reference of previous quarter with regards to excess dematerialised shares, if any.** N.A.

20. **Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?** N.A.

21. **Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:**

| Total No. of demat requests | No. of requests | No. of shares | Reasons for delay |
|------------------------------------|------------------------|----------------------|--------------------------|
| Confirmed after 21 days | NIL | NA | NA |
| Pending for more than 21 days | NIL | NA | NA |

22. **Name, Telephone & Fax No. of the Compliance Officer of the Co.** **CS Prachi Suhas Sathe**
M.No.: A70252
PAN No.: DWEPS5916N
Address: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063, Maharashtra.
Tel No.91674 91214

23. **Name, Address, Tel. & Fax No., Regn. no. of the Auditor** **DSM & Associates, Company Secretaries**
Sanam Umbargikar – Partner
103, Swaroop Center, Behind Satellite Building JB, Nagar, Andheri East, Mumbai-400099.
Mob: 81085 55704
C.P.No- 9394; M.No- 11777.

| | |
|--|---|
| 24. Appointment of common agency for share registry work, if yes (name & address) | MUFG Intime India Private Limited (Previously Known as Link Intime India Private Limited) SEBI Regn No. INR000004058 C-101, 247 Park, 1 st Floor, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083. |
|--|---|

| | |
|---|------|
| 5. Any other detail that the auditor may like to provide. (e. g. BIFR company, delisting from SE, company changed its name etc.) | N.A. |
|---|------|

For DSM & Associates,

Company Secretaries

UCN: P2015MH038100

Peer Review No.2229/2022

SANAM
 KASHINATH
 UMBARGIKAR

 Digitally signed by SANAM
 KASHINATH UMBARGIKAR
 Date: 2026.01.08 11:57:46
 +05'30'

CS Sanam Umbargikar

Partner

M.No.F11777.

COP No.9394.

UDIN: F011777G003189006.

Date: 8th January, 2026.

Place: Mumbai.